NPM1 and acute myeloid leukemia: Similarly, there was a trend for even longer OS (median OS; 75.2 vs 11 months; p = 0.0561) for PRDM16Low within AML patients with the triple-mutant NPM1/DNMT3A/FLT3-ITD (n = 114), but did not reach statistical significance due to the overall low number of PRDM16Low AML patients (n = 13) in this specific subgroup (Fig. 2E and F).